The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. / Vilsbøll, Tina; Agersø, Henrik; Lauritsen, Torsten; Deacon, Carolyn F; Aaboe, Kasper; Madsbad, Sten; Krarup, Thure; Holst, Jens Juul.

In: Regulatory Peptides, Vol. 137, No. 3, 2006, p. 168-72.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Vilsbøll, T, Agersø, H, Lauritsen, T, Deacon, CF, Aaboe, K, Madsbad, S, Krarup, T & Holst, JJ 2006, 'The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.', Regulatory Peptides, vol. 137, no. 3, pp. 168-72. https://doi.org/10.1016/j.regpep.2006.07.007

APA

Vilsbøll, T., Agersø, H., Lauritsen, T., Deacon, C. F., Aaboe, K., Madsbad, S., ... Holst, J. J. (2006). The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regulatory Peptides, 137(3), 168-72. https://doi.org/10.1016/j.regpep.2006.07.007

Vancouver

Vilsbøll T, Agersø H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S et al. The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regulatory Peptides. 2006;137(3):168-72. https://doi.org/10.1016/j.regpep.2006.07.007

Author

Vilsbøll, Tina ; Agersø, Henrik ; Lauritsen, Torsten ; Deacon, Carolyn F ; Aaboe, Kasper ; Madsbad, Sten ; Krarup, Thure ; Holst, Jens Juul. / The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. In: Regulatory Peptides. 2006 ; Vol. 137, No. 3. pp. 168-72.

Bibtex

@article{d0667200ab4911ddb5e9000ea68e967b,
title = "The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.",
abstract = "The incretin hormone, glucose-dependent insulinotropic polypeptide (GIP, previously known as gastric inhibitory polypeptide), is rapidly degraded to the biologically inactive metabolite GIP (3-42) in the circulation, but little is known about the kinetics of the intact hormone and the metabolite and whether differences exist between patients with type 2 diabetes mellitus and healthy subjects. We examined eight type 2 diabetic patients (six men, two women); mean (range) age: 59 (48-69) years; BMI: 31.6 (26.0-37.7) kg/m2; HbA1C: 9.0 (8.2-13.2) {\%}; fasting plasma glucose (FPG): 10.0 (8.3-13.2) mmol/l and 8 healthy subjects matched for age, gender and BMI. An intravenous bolus injection of GIP (7.5 nmol) was given and venous blood samples were drawn the following 45 minutes. Peak concentrations of total GIP (intact+metabolite, mean+/-SEM) and intact GIP (in brackets) were 920+/-91 (442+/-52) pmol/l in the type 2 diabetic patients and 775+/-68 (424+/-30) pmol/l in the healthy subjects (NS). GIP was eliminated rapidly with the clearance rate for intact GIP being 2.3+/-0.2 l/min in the type 2 diabetic patients and 2.4+/-0.2 l/min in the healthy subjects (NS). The volumes of distributions were similar in the two groups and ranged from 8 to 21 l per subject. The primary metabolite, GIP 3-42, generated through the action of dipeptidyl peptidase IV (DPP-IV), was eliminated with a mean half-life of 17.5 and 20.5 min in patients and healthy subjects (NS). CONCLUSION: Elimination of GIP is similar in obese type 2 diabetic patients and matched healthy subjects. Differences in elimination of GIP and its primary metabolite, therefore, do not seem to contribute to the defective insulinotropic effect of GIP in type 2 diabetes.",
author = "Tina Vilsb{\o}ll and Henrik Agers{\o} and Torsten Lauritsen and Deacon, {Carolyn F} and Kasper Aaboe and Sten Madsbad and Thure Krarup and Holst, {Jens Juul}",
note = "Keywords: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Humans; Injections, Intravenous; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Peptide Fragments",
year = "2006",
doi = "10.1016/j.regpep.2006.07.007",
language = "English",
volume = "137",
pages = "168--72",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

AU - Vilsbøll, Tina

AU - Agersø, Henrik

AU - Lauritsen, Torsten

AU - Deacon, Carolyn F

AU - Aaboe, Kasper

AU - Madsbad, Sten

AU - Krarup, Thure

AU - Holst, Jens Juul

N1 - Keywords: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Humans; Injections, Intravenous; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Peptide Fragments

PY - 2006

Y1 - 2006

N2 - The incretin hormone, glucose-dependent insulinotropic polypeptide (GIP, previously known as gastric inhibitory polypeptide), is rapidly degraded to the biologically inactive metabolite GIP (3-42) in the circulation, but little is known about the kinetics of the intact hormone and the metabolite and whether differences exist between patients with type 2 diabetes mellitus and healthy subjects. We examined eight type 2 diabetic patients (six men, two women); mean (range) age: 59 (48-69) years; BMI: 31.6 (26.0-37.7) kg/m2; HbA1C: 9.0 (8.2-13.2) %; fasting plasma glucose (FPG): 10.0 (8.3-13.2) mmol/l and 8 healthy subjects matched for age, gender and BMI. An intravenous bolus injection of GIP (7.5 nmol) was given and venous blood samples were drawn the following 45 minutes. Peak concentrations of total GIP (intact+metabolite, mean+/-SEM) and intact GIP (in brackets) were 920+/-91 (442+/-52) pmol/l in the type 2 diabetic patients and 775+/-68 (424+/-30) pmol/l in the healthy subjects (NS). GIP was eliminated rapidly with the clearance rate for intact GIP being 2.3+/-0.2 l/min in the type 2 diabetic patients and 2.4+/-0.2 l/min in the healthy subjects (NS). The volumes of distributions were similar in the two groups and ranged from 8 to 21 l per subject. The primary metabolite, GIP 3-42, generated through the action of dipeptidyl peptidase IV (DPP-IV), was eliminated with a mean half-life of 17.5 and 20.5 min in patients and healthy subjects (NS). CONCLUSION: Elimination of GIP is similar in obese type 2 diabetic patients and matched healthy subjects. Differences in elimination of GIP and its primary metabolite, therefore, do not seem to contribute to the defective insulinotropic effect of GIP in type 2 diabetes.

AB - The incretin hormone, glucose-dependent insulinotropic polypeptide (GIP, previously known as gastric inhibitory polypeptide), is rapidly degraded to the biologically inactive metabolite GIP (3-42) in the circulation, but little is known about the kinetics of the intact hormone and the metabolite and whether differences exist between patients with type 2 diabetes mellitus and healthy subjects. We examined eight type 2 diabetic patients (six men, two women); mean (range) age: 59 (48-69) years; BMI: 31.6 (26.0-37.7) kg/m2; HbA1C: 9.0 (8.2-13.2) %; fasting plasma glucose (FPG): 10.0 (8.3-13.2) mmol/l and 8 healthy subjects matched for age, gender and BMI. An intravenous bolus injection of GIP (7.5 nmol) was given and venous blood samples were drawn the following 45 minutes. Peak concentrations of total GIP (intact+metabolite, mean+/-SEM) and intact GIP (in brackets) were 920+/-91 (442+/-52) pmol/l in the type 2 diabetic patients and 775+/-68 (424+/-30) pmol/l in the healthy subjects (NS). GIP was eliminated rapidly with the clearance rate for intact GIP being 2.3+/-0.2 l/min in the type 2 diabetic patients and 2.4+/-0.2 l/min in the healthy subjects (NS). The volumes of distributions were similar in the two groups and ranged from 8 to 21 l per subject. The primary metabolite, GIP 3-42, generated through the action of dipeptidyl peptidase IV (DPP-IV), was eliminated with a mean half-life of 17.5 and 20.5 min in patients and healthy subjects (NS). CONCLUSION: Elimination of GIP is similar in obese type 2 diabetic patients and matched healthy subjects. Differences in elimination of GIP and its primary metabolite, therefore, do not seem to contribute to the defective insulinotropic effect of GIP in type 2 diabetes.

U2 - 10.1016/j.regpep.2006.07.007

DO - 10.1016/j.regpep.2006.07.007

M3 - Journal article

C2 - 16934887

VL - 137

SP - 168

EP - 172

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 3

ER -

ID: 8417003